IPP Bureau
Gamida Cell initiates rolling submission of Biologics License Application for Omidubicel
By IPP Bureau - February 10, 2022
On track to complete the BLA submission in the first half of 2022
Health Canada gives breakthrough approval for Dolphin Vagal Stim device to treat Covid-19
By IPP Bureau - February 10, 2022
The vagus nerve is the longest nerve in the body that travels down from the brain to innervate and control breathing, stress levels and inflammation
Skye Air Mobility to deploy drones to enhance Redcliffe Labs services
By IPP Bureau - February 10, 2022
Urban, semi-urban and remote corners of the country will be catered using drone delivery technology
Basf, Orbia Ventures invest in Israeli biotech startup
By IPP Bureau - February 10, 2022
FortePhest is developing a new technology to combat herbicide-resistant weeds and invasive plants
Glenmark launches nasal spray to treat Covid-19
By IPP Bureau - February 09, 2022
Glenmark received manufacturing and marketing approval from DCGI for Nitric Oxide Nasal Spray (NONS) as part of accelerated approval process
Scientists breaking barriers to treating heart failure
By IPP Bureau - February 09, 2022
Cysoni is a bionic device that paces the heart with real-time respiratory modulation. The innovation stems from the idea that heart rate increases and decreases with each breath in normal physiology, termed ‘respiratory sinus arrhythmia’ (RSA)
TATA MD’s OmiSure detects all Omicron variants
By IPP Bureau - February 09, 2022
According to ICMR, the upgraded OmiSure RT-PCR test for Covid-19 successfully detects all sub-types of Omicron that are currently prevalent in India
EdiGene and Neukio collaborate to develop next-generation immune cell therapies
By IPP Bureau - February 09, 2022
The collaboration will leverage EdiGene’s expertise in high-throughput genome editing screening and Neukio’s strength in the development and manufacturing of induced pluripotent stem cell (iPSC) and natural killer cell (NK Cell)
Strand Therapeutics appoints Dr. Prashant Nambiar as Senior VP
By IPP Bureau - February 09, 2022
Senior R&D leader from Pfizer and bluebird bio to support Strand’s platform of programmable mRNA-based therapeutics
C2i Genomics Partners with Twist Bioscience for cancer detection
By IPP Bureau - February 09, 2022
Twist will leverage C2i’s leadership in whole-genome cancer signatures across solid cancers to generate unique synthetic reference materials for cancer detection validation in labs across the globe
Piramal Pharma Solutions plans expansion in Scotland
By IPP Bureau - February 09, 2022
In the first phase of the Grangemouth site expansion, two new ADC manufacturing suites, operational by Q3 2023, will be added to the existing three
Lupin signs distribution agreement with Medis for Orphan Drug NaMuscla@
By IPP Bureau - February 09, 2022
NDM disorders are a group of rare, inherited neuromuscular disorders which is characterized by the inability to relax muscles following voluntary contraction
Dr Reddy’s launch generic version of Vasostrict in the US
By IPP Bureau - February 09, 2022
The Vasostrict brand market had U.S. sales of approximately US $ 878.5 million MAT for the most recent twelve months ending in December 2021 according to IQVIA Health
Abbott announces world's first implant of dual-chamber leadless pacemaker in pivotal trial
By IPP Bureau - February 08, 2022
Proprietary implant-to-implant (i2i) device technology is used for communication between two implanted leadless pacemakers to regulate the heart rate
Azurity Pharma gets USFDA approval for Fleqsuvy
By IPP Bureau - February 08, 2022
Nearly 1 million people are living with multiple sclerosis in the United States. Spasticity is a commonly reported symptom for MS, with an estimated prevalence of spasticity of 67%
